Quick Answer
Sonoma Pharmaceuticals, Inc. reported Long-Term Debt of $0.00 for fiscal year 2022.
Sonoma Pharmaceuticals, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2022 | $0.00 | -100.0% |
| 2021 | $1.31M | — |
| 2020 | $0.00 | -100.0% |
| 2019 | $12.0K | -62.5% |
| 2018 | $32.0K | -28.9% |
| 2017 | $45.0K | — |
| 2016 | $0.00 | — |
| 2015 | $0.00 | -100.0% |
| 2014 | $4.0K | -99.4% |
| 2013 | $676.0K | -62.9% |
| 2012 | $1.82M | +11.4% |
| 2011 | $1.64M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| December 31, 2022 | $15.0K | — | +0.0% |
| September 30, 2022 | $15.0K | — | +0.0% |
| June 30, 2022 | $15.0K | — | — |
| March 31, 2022 | $0.00 | -100.0% | — |
| September 30, 2021 | $0.00 | -100.0% | — |
| June 30, 2021 | $0.00 | -100.0% | -100.0% |
| March 31, 2021 | $1.31M | — | +0.0% |
| December 31, 2020 | $1.31M | — | +0.0% |
- Sonoma Pharmaceuticals, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2011–2022 period, Sonoma Pharmaceuticals, Inc.’s long-term debt has declined by 100.0% (from $1.64 million to $0.00).
- The most recent figure is from Sonoma Pharmaceuticals, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on July 13, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: